BNTX News

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

FairJourney Bio Opens Cryo-EM Structural Biology Facility in San Diego

DualityBio gibt Annahme des Zulassungsantrags für Trastuzumab Pamirtecan zur Behandlung von nicht resezierbarem oder metastasiertem HER2-positivem Brustkrebs bei erwachsenen Patienten durch die chinesische NMPA bekannt USA - Deutsch USA - English USA -

DualityBio annonce l'acceptation par la NMPA chinoise de la demande d'autorisation de mise sur le marché du trastuzumab pamirtecan pour le traitement du cancer du sein HER2 positif non résécable ou métastatique chez l'adulte USA - Français USA - English

DualityBio anuncia la aceptación de NMPA de China de su solicitud de licencia para productos biológicos USA - español USA - English USA - English

DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer USA - English USA - English

Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer

Feinstein Institutes 2026 Ross Prize awarded to Drs. Michel Sadelain and Carl H. June

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Intelligence Report 2026-2030: Industry Growth Driven by Personalized Treatment Adoption